Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,207 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Allogeneic transplantation Clear all
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

NCT00136903
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone, Prednisone, Cyclosporine, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

NCT00623935
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, Total Body Irradiation, Stem Cell Transplant
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 9, 2026, 3:23 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

NCT04263025
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cryopreserved Umbilical Cord Allograft, Robot-Assisted Radical Prostatectomy
Biological · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 9, 2026, 3:23 AM EDT
Completed No phase listed Observational

Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation

NCT04258891
View directory record Official record
Conditions
Kidney Transplant Failure
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Timeline
2004 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)

NCT00421174
View directory record Official record
Conditions
Pneumonia, Idiopathic Pneumonia Syndrome
Interventions
Etanercept, Placebo plus corticosteroid
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
12
States / cities
Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 3:23 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

NCT00061568
View directory record Official record
Conditions
Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions
Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wound Healing Following Tooth Extraction and Ridge Preservation Using DFDBA Alone in Particulate Fiber Form and in Combination With Xenograft

NCT05400213
View directory record Official record
Conditions
Dental Extraction, Wound Heal
Interventions
Vallos (DCP), Vallomix (DCF), Vallos-F (DPX), Vallomix-F (DFX)
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

NCT00052520
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, laboratory biomarker analysis, gene expression analysis, immunologic technique, flow cytometry, polymerase chain reaction, cytogenetic analysis, staining method
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 9, 2026, 3:23 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382
View directory record Official record
Conditions
Crohn Disease
Interventions
CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 9, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Results available

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

NCT00618540
View directory record Official record
Conditions
Histiocytosis, Langerhans-cell
Interventions
alemtuzumab, fludarabine phosphate, melphalan, stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

NCT01203020
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Busulfan, Fludarabine
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 1Phase 2 Interventional

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

NCT03977662
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Co-transplantation of PTG with pancreatic islets
Combination Product
Lead sponsor
Peter Stock
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)

NCT00912223
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
21
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 9, 2026, 3:23 AM EDT
Recruiting Not applicable Interventional

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

NCT06877169
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
Interventions
Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 9, 2026, 3:23 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Optimized Biventricular Pacing Allograft Recipients

NCT01290822
View directory record Official record
Conditions
Dilated Cardiomyopathy, Ischemic Cardiomyopathy
Interventions
BiVP, AAI Pacing
Device
Lead sponsor
Henry M. Spotnitz
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 2 Interventional Results available

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

NCT00134004
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 74 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 9, 2026, 3:23 AM EDT
Terminated Phase 2Phase 3 Interventional

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

NCT00038805
View directory record Official record
Conditions
Leukemia
Interventions
Mylotarg
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 9, 2026, 3:23 AM EDT
Recruiting Phase 2 Interventional

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

NCT04187105
View directory record Official record
Conditions
Acute Leukemia, MDS
Interventions
Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant
Radiation · Drug · Device + 1 more
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 9, 2026, 3:23 AM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

NCT00589602
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Secondary Myelofibrosis
Interventions
peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation (TBI)
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

NCT00107354
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes, cytarabine, etoposide, mitoxantrone hydrochloride, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2010 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 4 Interventional Results available

Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy

NCT02880137
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Perflutren Lipid Microsphere, RTMPE
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 9, 2026, 3:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease

NCT00001872
View directory record Official record
Conditions
Graft vs Host Disease, Hematologic Neoplasm
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 9, 2026, 3:23 AM EDT
Completed Phase 1 Interventional

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

NCT00854139
View directory record Official record
Conditions
Multiple Myeloma, End Stage Renal Disease
Interventions
Cyclophosphamide, anti-thymocyte globulin, Kidney transplant, Thymic irradiation, Bone marrow transplant from a related donor
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 9, 2026, 3:23 AM EDT